{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:58:48Z","timestamp":1791244728026,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.vaccine.2025.127628","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T15:22:09Z","timestamp":1755616929000},"page":"127628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Real-world safety of herpes zoster vaccines: A pharmacovigilance study based on the vaccine adverse event reporting system (may 2006\u2013december 2024)"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0075-879X","authenticated-orcid":false,"given":"Haixia","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beixi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2835-3601","authenticated-orcid":false,"given":"Shujuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2025.127628_bb0005","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/v14020192","article-title":"Herpes zoster: a review of clinical manifestations and management","volume":"14","author":"Patil","year":"2022","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127628_bb0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.vaccine.2022.10.063","article-title":"Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions","volume":"41","author":"Sullivan","year":"2023","journal-title":"Vaccine"},{"issue":"12 Suppl 2","key":"10.1016\/j.vaccine.2025.127628_bb0025","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.1093\/infdis\/jiab387","article-title":"Herpes zoster vaccines","volume":"224","author":"Harbecke","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127628_bb0030","article-title":"Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis","volume":"363","author":"Tricco","year":"2018","journal-title":"BMJ"},{"issue":"22","key":"10.1016\/j.vaccine.2025.127628_bb0035","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1016\/j.vaccine.2019.04.014","article-title":"The comparative efficacy and safety of herpes zoster vaccines: a network meta-analysis","volume":"37","author":"McGirr","year":"2019","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127628_bb0045","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1016\/j.vaccine.2024.03.024","article-title":"Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: data from active surveillance program. Puglia (Italy), 2021-23","volume":"42","author":"Stefanizzi","year":"2024","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127628_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24086967","article-title":"Immunogenicity and safety of adjuvanted recombinant zoster vaccine in rheumatoid arthritis patients on anti-cellular biologic agents or JAK inhibitors: a prospective observational study","volume":"24","author":"Venerito","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2025.127628_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2023.100397","article-title":"Efficacy and safety of the recombinant zoster vaccine: a systematic review and meta-analysis","volume":"15","author":"Zeevaert","year":"2023","journal-title":"Vaccine-X"},{"key":"10.1016\/j.vaccine.2025.127628_bb0060","article-title":"Vaccines for preventing herpes zoster in older adults","volume":"10","author":"de Oliveira","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"10.1016\/j.vaccine.2025.127628_bb0065","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1016\/j.vaccine.2024.03.066","article-title":"Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia","volume":"42","author":"Muttucumaru","year":"2024","journal-title":"Vaccine"},{"issue":"36","key":"10.1016\/j.vaccine.2025.127628_bb0070","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127628_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.2011652","article-title":"Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia region, 2014-19","volume":"18","author":"Stefanizzi","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127628_bb0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidem Dr S"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127628_bb0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel statistical tools for monitoring the safety of marketed drugs","volume":"82","author":"Almenoff","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127628_bb0100","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019S spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127628_bb0105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/aje\/kwac170","article-title":"Active postlicensure safety surveillance for recombinant zoster vaccine using electronic health record data","volume":"192","author":"Nelson","year":"2023","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127628_bb0110","first-page":"1","article-title":"Surveillance for safety after immunization: Vaccine adverse event reporting system (VAERS)--United States, 1991\u20132001","volume":"52","author":"Zhou","year":"2003","journal-title":"MMWR Surveill Summ"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127628_bb0115","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/aje\/kwac176","article-title":"Sequential data-mining for adverse events after recombinant herpes zoster vaccination using the tree-based scan statistic","volume":"192","author":"Yih","year":"2023","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127628_bb0120","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/aje\/kwac030","article-title":"A broad safety assessment of the recombinant herpes zoster vaccine","volume":"191","author":"Yih","year":"2022","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127628_bb0125","doi-asserted-by":"crossref","first-page":"91","DOI":"10.15585\/mmwr.mm6804a4","article-title":"Postlicensure safety surveillance of recombinant zoster vaccine (Shingrix) \u2014 United States, October 2017\u2013June 2018","volume":"68","author":"Hesse","year":"2019","journal-title":"Morb Mortal Wkly Rep"},{"issue":"18","key":"10.1016\/j.vaccine.2025.127628_bb0130","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1016\/j.vaccine.2019.11.058","article-title":"Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine","volume":"38","author":"Tavares-Da-Silva","year":"2020","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127628_bb0135","doi-asserted-by":"crossref","first-page":"2263979","DOI":"10.1080\/21645515.2023.2263979","article-title":"Effectiveness and safety of recombinant zoster vaccine: a review of real-world evidence","volume":"19","author":"Parikh","year":"2023","journal-title":"Hum Vacc Immunother"},{"key":"10.1016\/j.vaccine.2025.127628_bb0140","article-title":"Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017\u2013April 2024","volume":"50","author":"Shu","year":"2025","journal-title":"Prev Med Rep"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127628_bb0145","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1080\/21645515.2018.1456598","article-title":"Post-licensure safety surveillance of zoster vaccine live (Zostavax(R)) in the United States, vaccine adverse event reporting system (VAERS), 2006-2015","volume":"14","author":"Miller","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"52","key":"10.1016\/j.vaccine.2025.127628_bb0150","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1016\/j.vaccine.2017.11.013","article-title":"Herpes zoster vaccine live: a 10\u00a0year review of post-marketing safety experience","volume":"35","author":"Willis","year":"2017","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127628_bb0155","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s40264-021-01118-3","article-title":"An analysis of spontaneously reported data of vesicular and bullous cutaneous eruptions occurring following vaccination with the adjuvanted recombinant zoster vaccine","volume":"44","author":"Pirrotta","year":"2021","journal-title":"Drug Saf"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127628_bb0160","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jamainternmed.2021.6227","article-title":"Risk of Guillain-barre syndrome following recombinant zoster vaccine in medicare beneficiaries","volume":"181","author":"Goud","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.vaccine.2025.127628_bb0165","series-title":"Evaluation of the potential confounding effect of shingles on the risk of Guillain-Barr\u00e9 syndrome after vaccination with the recombinant zoster vaccine","author":"Haguinet","year":"2021"},{"key":"10.1016\/j.vaccine.2025.127628_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.869893","article-title":"Social media interventions strengthened COVID-19 immunization campaign","volume":"10","author":"Di Mauro","year":"2022","journal-title":"Front Pediatr"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127628_bb0175","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13690-024-01260-1","article-title":"Effectiveness of educational interventions for healthcare workers on vaccination dialogue with older adults: a systematic review","volume":"82","author":"Wennekes","year":"2024","journal-title":"Arch Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127628_bb0180","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2317595","article-title":"Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: qualitative interviews with healthcare providers and patients","volume":"20","author":"George","year":"2024","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127628_bb0185","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.ajic.2017.10.004","article-title":"Vaccination coverage in patients affected by chronic diseases: a 2014 cross-sectional study among subjects hospitalized at Bari Policlinico general hospital","volume":"46","author":"Gallone","year":"2018","journal-title":"Am J Infect Control"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T03:52:15Z","timestamp":1765857135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25009259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":32,"alternative-id":["S0264410X25009259"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127628","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world safety of herpes zoster vaccines: A pharmacovigilance study based on the vaccine adverse event reporting system (may 2006\u2013december 2024)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"127628"}}